Current Landscape of Immunotherapy in Breast Cancer: A Review

被引：326

作者：

Adams, Sylvia ^{[1
]}

Gatti-Mays, Margaret E. ^{[2
]}

Kalinsky, Kevin ^{[3
]}

Korde, Larissa A. ^{[4
]}

Sharon, Elad ^{[5
]}

Amiri-Kordestani, Laleh ^{[6
]}

Bear, Harry ^{[7
]}

McArthur, Heather L. ^{[8
]}

Frank, Elizabeth ^{[9
]}

Perlmutter, Jane ^{[10
]}

Page, David B. ^{[11
]}

Vincent, Benjamin ^{[12
]}

Hayes, Jennifer F. ^{[13
]}

Gulley, James L. ^{[14
]}

Litton, Jennifer K. ^{[15
]}

Hortobagyi, Gabriel N. ^{[15
]}

Chia, Stephen ^{[16
]}

Krop, Ian ^{[9
]}

White, Julia ^{[17
]}

Sparano, Joseph ^{[18
]}

Disis, Mary L. ^{[19
]}

Mittendorf, Elizabeth A. ^{[20
,21
]}

机构：

[1] NYU, Sch Med, Perlmutter Canc Ctr, New York, NY USA

[2] NCI, Lab Tumor Immunol & Biol, Bethesda, MD 20892 USA

[3] Columbia Univ, Med Ctr, New York, NY USA

[4] NCI, Clin Invest Branch, Canc Therapy & Evaluat Program, Div Canc Treatment & Diag, Rockville, MD USA

[5] NCI, Invest Drug Branch, Canc Therapy & Evaluat Program, Div Canc Treatment & Diag, Rockville, MD USA

[6] US FDA, Silver Spring, MD USA

[7] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA USA

[8] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA

[9] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA

[10] Gemini Grp, Ann Arbor, MI USA

[11] Providence Canc Inst, Earle A Chiles Res Inst, Portland, OR USA

[12] Univ N Carolina, Curriculum Bioinformat & Computat Biol, Lineberger Comprehens Canc Ctr, Dept Med,Div Hematol Oncol, Chapel Hill, NC 27515 USA

[13] NCI, Coordinating Ctr Clin Trials, Rockville, MD USA

[14] NCI, Genitourinary Malignancy Branch, Bethesda, MD 20892 USA

[15] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[16] British Columbia Canc Agcy, Vancouver, BC, Canada

[17] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA

[18] Montefiore Einstein Ctr Canc Care, New York, NY USA

[19] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[20] Brigham & Womens Hosp, Dept Surg, 75 Francis St, Boston, MA 02115 USA

[21] Dana Farber Brigham & Womens Canc Ctr, Breast Oncol Program, Boston, MA USA

来源：

JAMA ONCOLOGY | 2019年 / 5卷 / 08期

关键词：

TUMOR-INFILTRATING LYMPHOCYTES; CTLA-4; BLOCKADE; ANTITUMOR IMMUNITY; RADIATION-THERAPY; METASTATIC BREAST; PROGNOSTIC VALUE; PREDICTIVE-VALUE; LOCAL RADIATION; TRASTUZUMAB; RADIOTHERAPY;

D O I：

10.1001/jamaoncol.2018.7147

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

ImportanceThere is tremendous interest in using immunotherapy to treat breast cancer, as evidenced by the more than 290 clinical trials ongoing at the time of this narrative review. The objective of this review is to describe the current status of immunotherapy in breast cancer, highlighting its potential in both early-stage and metastatic disease. ObservationsAfter searching ClinicalTrials.gov on April 24, 2018, and PubMed up to June 30, 2018, to identify breast cancer immunotherapy trials, we found that immune checkpoint blockade (ICB) is the most investigated form of immunotherapy in breast cancer. Use of ICB as monotherapy has achieved objective responses in patients with breast cancer, with higher rates seen when administered in earlier lines of therapy. For responding patients, those responses are durable. More recent data suggest clinical efficacy when ICB is given in combination with chemotherapy. Ongoing studies are evaluating combination strategies pairing ICB with additional chemotherapeutic agents, targeted therapy, vaccines, and local ablative therapies to enhance response. To date, robust predictive biomarkers for response to ICB have not been established. Conclusions and RelevanceIt is anticipated that combination therapy strategies will be the way forward for immunotherapy in breast cancer, with an improved understanding of tumor, microenvironment, and host factors informing treatment combination decisions. Thoughtful study design incorporating appropriate end points and correlative studies will be critical in identifying optimal strategies for enhancing the immune response against breast tumors.

引用

页码：1205 / 1214

页数：10

共 74 条

[1]

Adams S, 2018, ANN ONCOL, DOI [10.1093/annonc/mdy51830475947, DOI 10.1093/ANNONC/MDY51830475947]

[2]

Adams S, 2018, JAMA Oncol

[3]

Adams S, 2018, ANN ONCOL, DOI [10.1093/annonc/mdy51730475950, DOI 10.1093/ANNONC/MDY51730475950]

[4]

Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199 [J].

Adams, Sylvia ;

Gray, Robert J. ;

Demaria, Sandra ;

Goldstein, Lori ;

Perez, Edith A. ;

Shulman, Lawrence N. ;

Martino, Silvana ;

Wang, Molin ;

Jones, Vicky E. ;

Saphner, Thomas J. ;

Wolff, Antonio C. ;

Wood, William C. ;

Davidson, Nancy E. ;

Sledge, George W. ;

Sparano, Joseph A. ;

Badve, Sunil S. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :2959-+

[5]

[Anonymous], JAMA ONCOL

[6]

[Anonymous], P AM SOC CLIN ONCO S

[7]

[Anonymous], CANC RES

[8]

Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma [J].

Barker, Christopher A. ;

Postow, Michael A. ;

Khan, Shaheer A. ;

Beal, Kathryn ;

Parhar, Preeti K. ;

Yamada, Yoshiya ;

Lee, Nancy Y. ;

Wolchok, Jedd D. .

CANCER IMMUNOLOGY RESEARCH, 2013, 1 (02) :92-98

[9]

Classical pathology and mutational load of breast cancer - integration of two worlds [J].

Budczies, Jan ;

Bockmayr, Michael ;

Denkert, Carsten ;

Klauschen, Frederick ;

Lennerz, Jochen K. ;

Gyorffy, Balazs ;

Dietel, Manfred ;

Loibl, Sibylle ;

Weichert, Wilko ;

Stenzinger, Albrecht .

JOURNAL OF PATHOLOGY CLINICAL RESEARCH, 2015, 1 (04) :225-238

[10]

Elements of cancer immunity and the cancer-immune set point [J].

Chen, Daniel S. ;

Mellman, Ira .

NATURE, 2017, 541 (7637) :321-330

← 1 2 3 4 5 6 7 8 →